Emcure Pharmaceuticals Ltd
EMCUREBSE 544210PharmaceuticalsMkt cap ₹36,872 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹2,580 Cr
YoY +22.8%QoQ +4.5%
Net profit · Q1 FY27
₹292 Cr
YoY +36.2%QoQ +20.0%
Net margin · Q1 FY27
11.3%
+1.1 pts vs Q1 FY26
Net profit · FY26
₹941 Cr
YoY +33.0%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 2,580 | 2,470 | 2,363 | 2,270 | 2,101 | +22.8% |
| Other income | 2.07 | 3.99 | 1.85 | 3.12 | 3.70 | -44.1% |
| Total income | 2,583 | 2,474 | 2,365 | 2,273 | 2,104 | +22.7% |
| Profit before tax | 394 | 341 | 314 | 341 | 291 | +35.3% |
| Tax | 101 | 97.44 | 82.42 | 90.05 | 75.96 | +33.0% |
| Net profit | 292 | 244 | 231 | 251 | 215 | +36.2% |
| Net margin | 11.3% | 9.9% | 9.8% | 11.1% | 10.2% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | YoY |
|---|---|---|---|
| Revenue | 9,204 | 7,896 | +16.6% |
| Other income | 12.66 | 67.26 | -81.2% |
| Total income | 9,216 | 7,963 | +15.7% |
| Profit before tax | 1,287 | 971 | +32.5% |
| Tax | 346 | 264 | +31.1% |
| Net profit | 941 | 707 | +33.0% |
| Net margin | 10.2% | 9.0% |
BIC's take
We haven't covered Emcure Pharmaceuticals Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:37 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.